{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/overcoming-recruitment-and-retention-challenges-prader-willi-syndrome-drug-development#webpage",
"url": "https://www.fortrea.com/insights/overcoming-recruitment-and-retention-challenges-prader-willi-syndrome-drug-development",
"name": "Overcoming Recruitment and Retention Challenges in Prader-Willi Syndrome Drug Development",
"description": "Explore this Fortrea white paper on overcoming recruitment and retention challenges in Prader-Willi Syndrome drug development and discover strategies for improving enrollment, retention, and patient engagement in rare disease clinical trials. The white paper examines key considerations for operationalizing Prader-Willi Syndrome studies, including patient and caregiver engagement, recruitment and retention planning, endpoint selection, protocol design considerations, advocacy group collaboration, and decentralized clinical trial methods that help reduce participant burden. Learn how patient-centric trial strategies, family-focused engagement approaches, rare disease recruitment methods, community partnerships, clinical trial operational planning, and retention-focused study designs are helping sponsors improve study execution, strengthen participant experiences, enhance enrollment outcomes, and support successful Prader-Willi Syndrome drug development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Overcoming Recruitment and Retention Challenges in Prader-Willi Syndrome Drug Development",
"item": "https://www.fortrea.com/insights/overcoming-recruitment-and-retention-challenges-prader-willi-syndrome-drug-development"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/overcoming-recruitment-and-retention-challenges-prader-willi-syndrome-drug-development#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/overcoming-recruitment-and-retention-challenges-prader-willi-syndrome-drug-development#webpage"
},
"headline": "Overcoming Recruitment and Retention Challenges in Prader-Willi Syndrome Drug Development",
"description": "Explore this Fortrea white paper on overcoming recruitment and retention challenges in Prader-Willi Syndrome drug development and discover strategies for improving enrollment, retention, and patient engagement in rare disease clinical trials. The white paper examines key considerations for operationalizing Prader-Willi Syndrome studies, including patient and caregiver engagement, recruitment and retention planning, endpoint selection, protocol design considerations, advocacy group collaboration, and decentralized clinical trial methods that help reduce participant burden. Learn how patient-centric trial strategies, family-focused engagement approaches, rare disease recruitment methods, community partnerships, clinical trial operational planning, and retention-focused study designs are helping sponsors improve study execution, strengthen participant experiences, enhance enrollment outcomes, and support successful Prader-Willi Syndrome drug development programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2026-02-13",
"dateModified": "2026-02-13",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2026-02/pws-recruitment-retention.pdf",
"encodingFormat": "application/pdf"
}
}
]
}